Viartis discussed the positive study results from
Post# of 30029
Posted On: 02/16/2015 9:59:34 AM
Viartis discussed the positive study results from Amarantus' Eltoprazine clinical trial published in BRAIN. Viartis highlighted that 5mg of Eltoprazine caused a significant reduction of L-dopa induced dyskinesias, as well as an antidyskinetic effect with 7.5 mg. Full study abstract and additional Parkinson's news available here: http://bit.ly/1yLLtG2
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼